{"transactions":[{"id":717094,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T22:01:55.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":37910,"price":8,"value":303280.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date."}],"balance_after":37910,"derivative":{"exercise_price":8,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":37910},"source":{"system":"sec-edgar","filing":"0001741850-26-000002","document":"wk-form4_1783029712.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741850/000174185026000002/wk-form4_1783029712.xml","form_type":"4"}},{"id":717093,"issuer":{"id":4670,"kind":"organization","name":"Xeris Biopharma Holdings, Inc.","symbol":"XERS"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T22:01:55.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":33582,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the \"Plan\"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date."}],"balance_after":33582,"source":{"system":"sec-edgar","filing":"0001741850-26-000002","document":"wk-form4_1783029712.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741850/000174185026000002/wk-form4_1783029712.xml","form_type":"4"}},{"id":991097,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-11-21T22:21:31.000Z","date":"2025-11-19","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options fully vest on December 1, 2026."}],"balance_after":12000,"derivative":{"exercise_price":10.16,"expiration_date":"2035-11-19","underlying":"Common Shares","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000912282-25-001290","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1509261/000091228225001290/form4.xml","form_type":"4"}},{"id":991096,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-11-21T22:21:31.000Z","date":"2025-11-19","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units which fully vest on December 1, 2026."}],"balance_after":58576,"source":{"system":"sec-edgar","filing":"0000912282-25-001290","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509261/000091228225001290/form4.xml","form_type":"4"}},{"id":1103516,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-06-23T13:12:29.000Z","date":"2025-06-13","kind":"purchase","planned":false,"acquired":true,"shares":3076,"price":3.25,"value":9997.0,"ownership":{"direct":true},"balance_after":37576,"source":{"system":"sec-edgar","filing":"0000912282-25-000699","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509261/000091228225000699/form4.xml","form_type":"4"}},{"id":1111124,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":true}}],"security":"Director Stock Options (Right to Buy)","published_at":"2025-06-13T22:52:09.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on July 1, 2026."}],"balance_after":5000,"derivative":{"exercise_price":4.39,"expiration_date":"2035-06-10","underlying":"Common Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000912282-25-000668","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1509261/000091228225000668/form4.xml","form_type":"4"}},{"id":1111123,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-06-13T22:52:09.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units which vest 100% on July 1, 2026."}],"balance_after":34500,"source":{"system":"sec-edgar","filing":"0000912282-25-000668","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509261/000091228225000668/form4.xml","form_type":"4"}},{"id":1258916,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":true}}],"security":"Director Stock Option (Right to Buy)","published_at":"2025-02-20T02:18:42.000Z","date":"2025-02-16","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 100% on March 1, 2026."}],"balance_after":15000,"derivative":{"exercise_price":4.61,"expiration_date":"2035-02-16","underlying":"Common Shares","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000912282-25-000178","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1509261/000091228225000178/form4.xml","form_type":"4"}},{"id":1258915,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":true}}],"security":"Common Shares","published_at":"2025-02-20T02:18:42.000Z","date":"2025-02-16","kind":"grant","planned":false,"acquired":true,"shares":25500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of restricted stock units which vest 100% on March 1, 2026."}],"balance_after":25500,"source":{"system":"sec-edgar","filing":"0000912282-25-000178","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509261/000091228225000178/form4.xml","form_type":"4"}},{"id":1670695,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":true}}],"security":"Director Stock Options (Right to Buy)","published_at":"2024-01-25T17:04:28.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in 36 equal monthly installments, beginning February 23, 2024."}],"balance_after":30000,"derivative":{"exercise_price":1.02,"expiration_date":"2034-01-23","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000912282-24-000075","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509261/000091228224000075/form4.xml","form_type":"4"}},{"id":1787182,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-06T21:08:54.000Z","date":"2023-09-01","kind":"grant","planned":true,"acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027."}],"balance_after":21500,"derivative":{"exercise_price":15.41,"expiration_date":"2033-09-01","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001689375-23-000062","document":"wf-form4_169403451511634.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000062/wf-form4_169403451511634.xml","form_type":"4"}},{"id":1787181,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-09-06T21:08:54.000Z","date":"2023-09-06","kind":"sale","planned":true,"acquired":false,"shares":21,"price":14,"value":294.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023."}],"balance_after":40037,"source":{"system":"sec-edgar","filing":"0001689375-23-000062","document":"wf-form4_169403451511634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000062/wf-form4_169403451511634.xml","form_type":"4"}},{"id":1787180,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-09-06T21:08:54.000Z","date":"2023-09-06","kind":"sale","planned":true,"acquired":false,"shares":871,"price":13.4647,"value":11727.7537,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":40058,"source":{"system":"sec-edgar","filing":"0001689375-23-000062","document":"wf-form4_169403451511634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000062/wf-form4_169403451511634.xml","form_type":"4"}},{"id":1787179,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-09-06T21:08:54.000Z","date":"2023-09-05","kind":"tax_withholding","planned":true,"acquired":false,"shares":401,"price":14.4625,"value":5799.4625,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs."}],"balance_after":40929,"source":{"system":"sec-edgar","filing":"0001689375-23-000062","document":"wf-form4_169403451511634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000062/wf-form4_169403451511634.xml","form_type":"4"}},{"id":1787178,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-09-06T21:08:54.000Z","date":"2023-09-01","kind":"grant","planned":true,"acquired":true,"shares":14200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":41330,"source":{"system":"sec-edgar","filing":"0001689375-23-000062","document":"wf-form4_169403451511634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000062/wf-form4_169403451511634.xml","form_type":"4"}},{"id":1814986,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-04T20:50:05.000Z","date":"2023-08-04","kind":"exercise","planned":true,"acquired":false,"shares":6898,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":88012,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":6898},"source":{"system":"sec-edgar","filing":"0001689375-23-000050","document":"wf-form4_169118219238022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000050/wf-form4_169118219238022.xml","form_type":"4"}},{"id":1814985,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-04T20:50:05.000Z","date":"2023-08-03","kind":"exercise","planned":true,"acquired":false,"shares":9464,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":94910,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":9464},"source":{"system":"sec-edgar","filing":"0001689375-23-000050","document":"wf-form4_169118219238022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000050/wf-form4_169118219238022.xml","form_type":"4"}},{"id":1814984,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-04T20:50:05.000Z","date":"2023-08-02","kind":"exercise","planned":true,"acquired":false,"shares":10348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":104374,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":10348},"source":{"system":"sec-edgar","filing":"0001689375-23-000050","document":"wf-form4_169118219238022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000050/wf-form4_169118219238022.xml","form_type":"4"}},{"id":1814983,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-04T20:50:05.000Z","date":"2023-08-04","kind":"sale","planned":true,"acquired":false,"shares":6898,"price":14.1376,"value":97521.1648,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":27130,"source":{"system":"sec-edgar","filing":"0001689375-23-000050","document":"wf-form4_169118219238022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000050/wf-form4_169118219238022.xml","form_type":"4"}},{"id":1814982,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-04T20:50:05.000Z","date":"2023-08-04","kind":"exercise","planned":true,"acquired":true,"shares":6898,"price":2.1,"value":14485.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023."}],"balance_after":34028,"source":{"system":"sec-edgar","filing":"0001689375-23-000050","document":"wf-form4_169118219238022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000050/wf-form4_169118219238022.xml","form_type":"4"}},{"id":1814981,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-04T20:50:05.000Z","date":"2023-08-03","kind":"sale","planned":true,"acquired":false,"shares":9464,"price":14.7432,"value":139529.6448,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.44 to $15.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":27130,"source":{"system":"sec-edgar","filing":"0001689375-23-000050","document":"wf-form4_169118219238022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000050/wf-form4_169118219238022.xml","form_type":"4"}},{"id":1814980,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-04T20:50:05.000Z","date":"2023-08-03","kind":"exercise","planned":true,"acquired":true,"shares":9464,"price":2.1,"value":19874.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023."}],"balance_after":36594,"source":{"system":"sec-edgar","filing":"0001689375-23-000050","document":"wf-form4_169118219238022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000050/wf-form4_169118219238022.xml","form_type":"4"}},{"id":1814979,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-04T20:50:05.000Z","date":"2023-08-02","kind":"sale","planned":true,"acquired":false,"shares":68,"price":16.82,"value":1143.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023."}],"balance_after":27130,"source":{"system":"sec-edgar","filing":"0001689375-23-000050","document":"wf-form4_169118219238022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000050/wf-form4_169118219238022.xml","form_type":"4"}},{"id":1814978,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-04T20:50:05.000Z","date":"2023-08-02","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":16.0117,"value":16011.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $16.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":27198,"source":{"system":"sec-edgar","filing":"0001689375-23-000050","document":"wf-form4_169118219238022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000050/wf-form4_169118219238022.xml","form_type":"4"}},{"id":1814977,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-04T20:50:05.000Z","date":"2023-08-02","kind":"sale","planned":true,"acquired":false,"shares":9280,"price":15.0876,"value":140012.928,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.74 to $15.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":28198,"source":{"system":"sec-edgar","filing":"0001689375-23-000050","document":"wf-form4_169118219238022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000050/wf-form4_169118219238022.xml","form_type":"4"}},{"id":1814976,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-08-04T20:50:05.000Z","date":"2023-08-02","kind":"exercise","planned":true,"acquired":true,"shares":10348,"price":2.1,"value":21730.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023."}],"balance_after":37478,"source":{"system":"sec-edgar","filing":"0001689375-23-000050","document":"wf-form4_169118219238022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000050/wf-form4_169118219238022.xml","form_type":"4"}},{"id":1917236,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-19T21:48:05.000Z","date":"2023-03-01","kind":"grant","planned":false,"acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively."}],"balance_after":21500,"derivative":{"exercise_price":12.25,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001689375-23-000027","document":"wf-form4a_168194087335878.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000027/wf-form4a_168194087335878.xml","form_type":"4/A","original_submission_date":"2023-03-03"}},{"id":1917235,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-04-19T21:48:05.000Z","date":"2023-03-01","kind":"grant","planned":false,"acquired":true,"shares":14200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person's original Form 4, filed on March 3, 2023, is being amended by this Form 4A solely to correct an administrative error, which misreported a grant that occurred on March 1, 2023 as a total of 43,000 option shares and 28,400 RSUs, when in fact 21,500 option shares and 14,200 RSUs were granted as of that date, accurately reflecting that these grants are semi-annual. As a result of this administrative error, the number of shares beneficially owned by the Reporting Person following the corrected transaction reflects a reduction by 50% in the number of RSUs and option shares, respectively, reported as beneficially owned by the Reporting Person by 21,500 option shares and 14,200 RSUs, respectively."}],"balance_after":27130,"source":{"system":"sec-edgar","filing":"0001689375-23-000027","document":"wf-form4a_168194087335878.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000027/wf-form4a_168194087335878.xml","form_type":"4/A","original_submission_date":"2023-03-03"}},{"id":1973765,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-03T21:32:04.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":43000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the option shares shall vest and become exercisable on March 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2027."}],"balance_after":43000,"derivative":{"exercise_price":12.25,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":43000},"source":{"system":"sec-edgar","filing":"0001689375-23-000011","document":"wf-form4_167787905815593.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000011/wf-form4_167787905815593.xml","form_type":"4"}},{"id":1973764,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:32:04.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":164,"price":11.2227,"value":1840.5228,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.04 to $11.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41330,"source":{"system":"sec-edgar","filing":"0001689375-23-000011","document":"wf-form4_167787905815593.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000011/wf-form4_167787905815593.xml","form_type":"4"}},{"id":1973763,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:32:04.000Z","date":"2023-03-02","kind":"sale","acquired":false,"shares":1477,"price":10.4912,"value":15495.5024,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.04 to $11.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":41494,"source":{"system":"sec-edgar","filing":"0001689375-23-000011","document":"wf-form4_167787905815593.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000011/wf-form4_167787905815593.xml","form_type":"4"}},{"id":1973762,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:32:04.000Z","date":"2023-03-02","kind":"tax_withholding","acquired":false,"shares":945,"price":11.5962,"value":10958.409,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs."}],"balance_after":42971,"source":{"system":"sec-edgar","filing":"0001689375-23-000011","document":"wf-form4_167787905815593.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000011/wf-form4_167787905815593.xml","form_type":"4"}},{"id":1973761,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-03T21:32:04.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":28400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2024; (ii) 25% on March 1, 2025; (iii) 25% on March 1, 2026 and (iv) the remaining 25% on March 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":43916,"source":{"system":"sec-edgar","filing":"0001689375-23-000011","document":"wf-form4_167787905815593.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000011/wf-form4_167787905815593.xml","form_type":"4"}},{"id":2072663,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-03T21:32:21.000Z","date":"2022-12-30","kind":"sale","acquired":false,"shares":5200,"price":13.4484,"value":69931.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.09 to $14.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":15516,"source":{"system":"sec-edgar","filing":"0001689375-23-000001","document":"wf-form4_167278151155209.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937523000001/wf-form4_167278151155209.xml","form_type":"4"}},{"id":2131035,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-27T22:49:07.000Z","date":"2022-10-26","kind":"exercise","acquired":false,"shares":4960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":114722,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":20716},"source":{"system":"sec-edgar","filing":"0001689375-22-000039","document":"wf-form4_166691093179410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000039/wf-form4_166691093179410.xml","form_type":"4"}},{"id":2131034,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-27T22:49:07.000Z","date":"2022-10-25","kind":"exercise","acquired":false,"shares":8040,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"The Form 4 filed by the reporting person on September 12, 2022 inadvertently understated the number of shares remaining subject to this option following the transactions reported therein by 111,690 shares, an error that was carried forward onto the reporting person's subsequent Form 4 filings. Prior to the transactions reported herein, the correct number of shares remaining subject to this option was 127,722 shares."}],"balance_after":119682,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":25033},"source":{"system":"sec-edgar","filing":"0001689375-22-000039","document":"wf-form4_166691093179410.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000039/wf-form4_166691093179410.xml","form_type":"4"}},{"id":2131033,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-10-27T22:49:07.000Z","date":"2022-10-26","kind":"sale","acquired":false,"shares":4317,"price":22.0108,"value":95020.6236,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.79 to $22.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20716,"source":{"system":"sec-edgar","filing":"0001689375-22-000039","document":"wf-form4_166691093179410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000039/wf-form4_166691093179410.xml","form_type":"4"}},{"id":2131032,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-10-27T22:49:07.000Z","date":"2022-10-26","kind":"sale","acquired":false,"shares":643,"price":21.2104,"value":13638.2872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.79 to $21.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":25033,"source":{"system":"sec-edgar","filing":"0001689375-22-000039","document":"wf-form4_166691093179410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000039/wf-form4_166691093179410.xml","form_type":"4"}},{"id":2131031,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-10-27T22:49:07.000Z","date":"2022-10-26","kind":"exercise","acquired":true,"shares":4960,"price":2.1,"value":10416.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."}],"balance_after":25676,"source":{"system":"sec-edgar","filing":"0001689375-22-000039","document":"wf-form4_166691093179410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000039/wf-form4_166691093179410.xml","form_type":"4"}},{"id":2131030,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-10-27T22:49:07.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":100,"price":22.13,"value":2213.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."}],"balance_after":20716,"source":{"system":"sec-edgar","filing":"0001689375-22-000039","document":"wf-form4_166691093179410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000039/wf-form4_166691093179410.xml","form_type":"4"}},{"id":2131029,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-10-27T22:49:07.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":2998,"price":21.4193,"value":64215.0614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.01 to $21.895, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20816,"source":{"system":"sec-edgar","filing":"0001689375-22-000039","document":"wf-form4_166691093179410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000039/wf-form4_166691093179410.xml","form_type":"4"}},{"id":2131028,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-10-27T22:49:07.000Z","date":"2022-10-25","kind":"sale","acquired":false,"shares":4942,"price":20.5305,"value":101461.731,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":23814,"source":{"system":"sec-edgar","filing":"0001689375-22-000039","document":"wf-form4_166691093179410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000039/wf-form4_166691093179410.xml","form_type":"4"}},{"id":2131027,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-10-27T22:49:07.000Z","date":"2022-10-25","kind":"exercise","acquired":true,"shares":8040,"price":2.1,"value":16884.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."}],"balance_after":28756,"source":{"system":"sec-edgar","filing":"0001689375-22-000039","document":"wf-form4_166691093179410.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000039/wf-form4_166691093179410.xml","form_type":"4"}},{"id":2149960,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-28T21:10:49.000Z","date":"2022-09-28","kind":"exercise","acquired":false,"shares":3122,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":16032,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":3122},"source":{"system":"sec-edgar","filing":"0001689375-22-000033","document":"wf-form4_166439943270541.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000033/wf-form4_166439943270541.xml","form_type":"4"}},{"id":2149959,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-28T21:10:49.000Z","date":"2022-09-27","kind":"exercise","acquired":false,"shares":2403,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":19154,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":2403},"source":{"system":"sec-edgar","filing":"0001689375-22-000033","document":"wf-form4_166439943270541.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000033/wf-form4_166439943270541.xml","form_type":"4"}},{"id":2149958,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-28T21:10:49.000Z","date":"2022-09-26","kind":"exercise","acquired":false,"shares":3068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":21557,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":3068},"source":{"system":"sec-edgar","filing":"0001689375-22-000033","document":"wf-form4_166439943270541.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000033/wf-form4_166439943270541.xml","form_type":"4"}},{"id":2149957,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-28T21:10:49.000Z","date":"2022-09-28","kind":"sale","acquired":false,"shares":3122,"price":15.2497,"value":47609.5634,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20716,"source":{"system":"sec-edgar","filing":"0001689375-22-000033","document":"wf-form4_166439943270541.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000033/wf-form4_166439943270541.xml","form_type":"4"}},{"id":2149956,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-28T21:10:49.000Z","date":"2022-09-28","kind":"exercise","acquired":true,"shares":3122,"price":2.1,"value":6556.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."}],"balance_after":23838,"source":{"system":"sec-edgar","filing":"0001689375-22-000033","document":"wf-form4_166439943270541.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000033/wf-form4_166439943270541.xml","form_type":"4"}},{"id":2149955,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-28T21:10:49.000Z","date":"2022-09-27","kind":"sale","acquired":false,"shares":2403,"price":15.3096,"value":36788.9688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20716,"source":{"system":"sec-edgar","filing":"0001689375-22-000033","document":"wf-form4_166439943270541.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000033/wf-form4_166439943270541.xml","form_type":"4"}},{"id":2149954,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-28T21:10:49.000Z","date":"2022-09-27","kind":"exercise","acquired":true,"shares":2403,"price":2.1,"value":5046.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."}],"balance_after":23119,"source":{"system":"sec-edgar","filing":"0001689375-22-000033","document":"wf-form4_166439943270541.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000033/wf-form4_166439943270541.xml","form_type":"4"}},{"id":2149953,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-28T21:10:49.000Z","date":"2022-09-26","kind":"sale","acquired":false,"shares":300,"price":16.33,"value":4899.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.20 to $16.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20716,"source":{"system":"sec-edgar","filing":"0001689375-22-000033","document":"wf-form4_166439943270541.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000033/wf-form4_166439943270541.xml","form_type":"4"}},{"id":2149952,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-28T21:10:49.000Z","date":"2022-09-26","kind":"sale","acquired":false,"shares":2768,"price":15.2206,"value":42130.6208,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":21016,"source":{"system":"sec-edgar","filing":"0001689375-22-000033","document":"wf-form4_166439943270541.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000033/wf-form4_166439943270541.xml","form_type":"4"}},{"id":2149951,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-28T21:10:49.000Z","date":"2022-09-26","kind":"exercise","acquired":true,"shares":3068,"price":2.1,"value":6442.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."}],"balance_after":23784,"source":{"system":"sec-edgar","filing":"0001689375-22-000033","document":"wf-form4_166439943270541.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000033/wf-form4_166439943270541.xml","form_type":"4"}},{"id":2152023,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-23T20:57:42.000Z","date":"2022-09-23","kind":"exercise","acquired":false,"shares":939,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":24625,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":939},"source":{"system":"sec-edgar","filing":"0001689375-22-000030","document":"wf-form4_166396664564604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000030/wf-form4_166396664564604.xml","form_type":"4"}},{"id":2152022,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-23T20:57:42.000Z","date":"2022-09-21","kind":"exercise","acquired":false,"shares":3341,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":25564,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":3341},"source":{"system":"sec-edgar","filing":"0001689375-22-000030","document":"wf-form4_166396664564604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000030/wf-form4_166396664564604.xml","form_type":"4"}},{"id":2152021,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-23T20:57:42.000Z","date":"2022-09-23","kind":"sale","acquired":false,"shares":939,"price":15.0871,"value":14166.7869,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20716,"source":{"system":"sec-edgar","filing":"0001689375-22-000030","document":"wf-form4_166396664564604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000030/wf-form4_166396664564604.xml","form_type":"4"}},{"id":2152020,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-23T20:57:42.000Z","date":"2022-09-23","kind":"exercise","acquired":true,"shares":939,"price":2.1,"value":1971.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."}],"balance_after":21655,"source":{"system":"sec-edgar","filing":"0001689375-22-000030","document":"wf-form4_166396664564604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000030/wf-form4_166396664564604.xml","form_type":"4"}},{"id":2152019,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-23T20:57:42.000Z","date":"2022-09-21","kind":"sale","acquired":false,"shares":3341,"price":15.0833,"value":50393.3053,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20716,"source":{"system":"sec-edgar","filing":"0001689375-22-000030","document":"wf-form4_166396664564604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000030/wf-form4_166396664564604.xml","form_type":"4"}},{"id":2152018,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-23T20:57:42.000Z","date":"2022-09-21","kind":"exercise","acquired":true,"shares":3341,"price":2.1,"value":7016.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."}],"balance_after":24057,"source":{"system":"sec-edgar","filing":"0001689375-22-000030","document":"wf-form4_166396664564604.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000030/wf-form4_166396664564604.xml","form_type":"4"}},{"id":2155757,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-19T20:32:37.000Z","date":"2022-09-15","kind":"exercise","acquired":false,"shares":106,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":28905,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":106},"source":{"system":"sec-edgar","filing":"0001689375-22-000026","document":"wf-form4_166361953637742.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000026/wf-form4_166361953637742.xml","form_type":"4"}},{"id":2155756,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-19T20:32:37.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":106,"price":15.0134,"value":1591.4204,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.01 to $15.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20716,"source":{"system":"sec-edgar","filing":"0001689375-22-000026","document":"wf-form4_166361953637742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000026/wf-form4_166361953637742.xml","form_type":"4"}},{"id":2155755,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-19T20:32:37.000Z","date":"2022-09-15","kind":"exercise","acquired":true,"shares":106,"price":2.1,"value":222.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."}],"balance_after":20822,"source":{"system":"sec-edgar","filing":"0001689375-22-000026","document":"wf-form4_166361953637742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000026/wf-form4_166361953637742.xml","form_type":"4"}},{"id":2161286,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-12T20:18:42.000Z","date":"2022-09-09","kind":"exercise","acquired":false,"shares":800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":29011,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0001689375-22-000020","document":"wf-form4_166301390290805.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000020/wf-form4_166301390290805.xml","form_type":"4"}},{"id":2161285,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-12T20:18:42.000Z","date":"2022-09-08","kind":"exercise","acquired":false,"shares":1221,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":29811,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":1221},"source":{"system":"sec-edgar","filing":"0001689375-22-000020","document":"wf-form4_166301390290805.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000020/wf-form4_166301390290805.xml","form_type":"4"}},{"id":2161284,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-12T20:18:42.000Z","date":"2022-09-09","kind":"sale","acquired":false,"shares":800,"price":15.0669,"value":12053.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20716,"source":{"system":"sec-edgar","filing":"0001689375-22-000020","document":"wf-form4_166301390290805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000020/wf-form4_166301390290805.xml","form_type":"4"}},{"id":2161283,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-12T20:18:42.000Z","date":"2022-09-09","kind":"exercise","acquired":true,"shares":800,"price":2.1,"value":1680.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."}],"balance_after":21516,"source":{"system":"sec-edgar","filing":"0001689375-22-000020","document":"wf-form4_166301390290805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000020/wf-form4_166301390290805.xml","form_type":"4"}},{"id":2161282,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-12T20:18:42.000Z","date":"2022-09-08","kind":"sale","acquired":false,"shares":1221,"price":15.1333,"value":18477.7593,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":20716,"source":{"system":"sec-edgar","filing":"0001689375-22-000020","document":"wf-form4_166301390290805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000020/wf-form4_166301390290805.xml","form_type":"4"}},{"id":2161281,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-12T20:18:42.000Z","date":"2022-09-08","kind":"exercise","acquired":true,"shares":1221,"price":2.1,"value":2564.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022."}],"balance_after":21937,"source":{"system":"sec-edgar","filing":"0001689375-22-000020","document":"wf-form4_166301390290805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000168937522000020/wf-form4_166301390290805.xml","form_type":"4"}},{"id":2165700,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-06T20:32:57.000Z","date":"2022-09-01","kind":"grant","acquired":true,"shares":5172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective\nas of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024;\n(iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective\nas of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024;\n(iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":20716,"source":{"system":"sec-edgar","filing":"0001104659-22-097874","document":"tm2225276-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922097874/tm2225276-3_4seq1.xml","form_type":"4"}},{"id":2212014,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-06T20:19:07.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":31032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shares shall vest and become exercisable on July 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on July 1, 2026."}],"balance_after":31032,"derivative":{"exercise_price":12,"expiration_date":"2032-07-01","underlying":"Common stock","underlying_shares":31032},"source":{"system":"sec-edgar","filing":"0001104659-22-077709","document":"tm2220515-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922077709/tm2220515-4_4seq1.xml","form_type":"4"}},{"id":2220915,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-27T21:30:58.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Options shall vest on the first day of the month following Grant Date and each month thereafter on the first day of each month [until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service."}],"balance_after":80000,"derivative":{"exercise_price":3.4,"expiration_date":"2032-06-23","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001567619-22-013407","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509261/000156761922013407/doc1.xml","form_type":"4"}},{"id":2354628,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T21:09:42.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":62063,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026."}],"balance_after":62063,"derivative":{"exercise_price":11.57,"expiration_date":"2032-03-01","underlying":"Common stock","underlying_shares":62063},"source":{"system":"sec-edgar","filing":"0001104659-22-030005","document":"tm228284-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922030005/tm228284-3_4seq1.xml","form_type":"4"}},{"id":2354627,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-03T21:09:42.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":10344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date."}],"balance_after":15544,"source":{"system":"sec-edgar","filing":"0001104659-22-030005","document":"tm228284-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465922030005/tm228284-3_4seq1.xml","form_type":"4"}},{"id":2457156,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-29T21:26:17.000Z","date":"2021-12-29","kind":"other","acquired":false,"shares":5200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option vested and became exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":142722,"derivative":{"exercise_price":2.1,"expiration_date":"2030-12-01","underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001104659-21-154295","document":"tm2136524-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465921154295/tm2136524-1_4seq1.xml","form_type":"4"}},{"id":2457155,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-29T21:26:17.000Z","date":"2021-12-29","kind":"exercise","acquired":true,"shares":5200,"price":2.1,"value":10920.0,"ownership":{"direct":true},"balance_after":5200,"source":{"system":"sec-edgar","filing":"0001104659-21-154295","document":"tm2136524-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465921154295/tm2136524-1_4seq1.xml","form_type":"4"}},{"id":2530726,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-01T23:00:07.000Z","date":"2021-10-28","kind":"grant","acquired":true,"shares":72012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in 48 equal monthly installments commencing on October 28, 2021 (the \"Vesting Start Date\"), such that the option shares shall be fully vested on the four-year anniversary of the Vesting Start Date."}],"balance_after":72012,"derivative":{"exercise_price":20,"expiration_date":"2031-10-28","underlying":"Common stock","underlying_shares":72012},"source":{"system":"sec-edgar","filing":"0001104659-21-132478","document":"tm2131250-15_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1689375/000110465921132478/tm2131250-15_4seq1.xml","form_type":"4"}},{"id":2633851,"issuer":{"id":1990,"kind":"organization","name":"Rezolute, Inc.","symbol":"RZLT"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-15T01:05:47.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Options shall vest on the first day of the month following Grant Date and each month thereafter on the first day of each month [until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service."}],"balance_after":10000,"derivative":{"exercise_price":12.28,"expiration_date":"2031-06-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001567619-21-013439","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1509261/000156761921013439/doc1.xml","form_type":"4"}},{"id":3793230,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-10-10T22:05:27.000Z","date":"2018-10-08","kind":"exercise","acquired":false,"shares":2942,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares vested on June 13, 2018 and the remaining 75% vest in equal monthly installments thereafter over a three-year period."}],"balance_after":24629,"derivative":{"exercise_price":0.91,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":2942},"source":{"system":"sec-edgar","filing":"0000899243-18-026507","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000089924318026507/doc4.xml","form_type":"4"}},{"id":3793229,"issuer":{"id":5328,"kind":"organization","name":"Tectonic Therapeutic, Inc.","symbol":"TECX"},"owners":[{"id":32607,"kind":"person","name":"KREHER NERISSA","position":1,"cik":"0001741850","reported_name":"KREHER NERISSA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-10-10T22:05:27.000Z","date":"2018-10-08","kind":"exercise","acquired":true,"shares":2942,"price":0.91,"value":2677.22,"ownership":{"direct":true},"balance_after":2942,"source":{"system":"sec-edgar","filing":"0000899243-18-026507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1681087/000089924318026507/doc4.xml","form_type":"4"}}]}